Vitamin K2 (menaquinone) is a family of vitamin K compounds characterised by a long polyunsaturated side chain that allows them to penetrate soft tissues — including arterial walls — unlike the shorter-chain vitamin K1 (phylloquinone), which is preferentially taken up by the liver and is relatively inefficient at extrahepatic tissue distribution. K2 exists in multiple forms (menaquinone-4 through menaquinone-14), of which MK-4 (menaquinone-4) and MK-7 (menaquinone-7) are the most clinically relevant. What makes K2 critically important for cardiovascular protection is its role as the essential cofactor for the enzyme gamma-glutamyl carboxylase, which activates the matrix Gla protein (MGP) — the most potent inhibitor of vascular calcification known. Without adequate K2, MGP remains inactive, and calcium deposits freely in arterial walls, accelerating atherosclerosis and increasing the risk of cardiovascular events.
The Mechanism of Vascular Calcification Inhibition
Calcium is essential for bone health — it provides the mineral matrix that gives bone its hardness and structural integrity — but it is potentially destructive when deposited in soft tissues, particularly the arterial wall. Vascular calcification (the deposition of calcium phosphate crystals in the walls of arteries) is a major independent risk factor for cardiovascular disease, and its presence is strongly associated with increased risk of heart attack, stroke, and cardiovascular mortality. MGP is a small protein secreted by vascular smooth muscle cells that is produced in an inactive form and requires vitamin K-dependent carboxylation (activation) by gamma-glutamyl carboxylase to become functional. Activated MGP circulates in the blood and prevents calcium crystals from forming in the arterial wall — it acts as a direct inhibitor of hydroxyapatite crystal formation in soft tissues.
The relationship between K2, MGP, and vascular calcification is well-established: studies in CKD patients (who have a very high burden of vascular calcification) show that inactive MGP levels are strongly correlated with vascular calcification burden, cardiovascular events, and mortality. K2 supplementation increases the carboxylation (activation) of MGP, reducing inactive MGP levels and decreasing the rate of vascular calcification progression. This is why K2 supplementation appears to be protective in populations at high risk of vascular calcification — including CKD patients, diabetics, and older adults — and why the combination of vitamin D (which increases calcium absorption and can accelerate vascular calcification if given without K2) and K2 is more cardiovascularly protective than vitamin D alone.
Clinical Evidence
The clinical evidence for K2 in cardiovascular protection is compelling. A prospective cohort study in 4,807 Dutch adults followed for 7-10 years found that high dietary K2 intake (predominantly MK-7 from cheese) was associated with approximately 50% lower risk of coronary heart disease and approximately 50% lower all-cause mortality compared to low K2 intake, after adjustment for confounders. A second prospective cohort study in 16,000 Italians confirmed these findings, with higher K2 intake associated with reduced cardiovascular mortality. A double-blind RCT in 244 post-menopausal women with osteopenia found that K2 (MK-7) at 180mcg daily for 3 years significantly reduced vertebral fracture incidence, increased bone mineral density in the lumbar spine and femoral neck, and did not accelerate vascular calcification — in contrast to calcium supplementation alone, which has been associated with accelerated vascular calcification in some studies.
Vitamin D and K2: The Essential Combination
The relationship between vitamins D and K2 is particularly important for supplement formulators and consumers to understand. Vitamin D increases calcium absorption from the intestine, which is beneficial for bone health but potentially harmful to arteries if not accompanied by adequate K2 — the increased calcium load must be directed toward bone rather than arteries, and K2-activated MGP is what performs that directional function. Studies show that vitamin D supplementation without adequate K2 may actually accelerate vascular calcification in people with pre-existing arterial stiffness. The combination of vitamin D plus K2, on the other hand, improves calcium distribution — more calcium goes to bone and less to arteries — producing better bone outcomes without the cardiovascular risk of vitamin D alone. This is why any comprehensive bone health or cardiovascular protection supplement should include both vitamin D and K2 in appropriate ratios.
Practical Application
For cardiovascular protection and bone health, the evidence-based dose is 90-200mcg of MK-7 daily, or 5-15mg of MK-4 daily (the doses used in the clinical trials showing bone and cardiovascular benefits). K2 should always be combined with vitamin D (which is essential for calcium absorption and bone mineralisation) and with adequate calcium intake (from diet or supplementation). Vitamin D without K2 may actually accelerate vascular calcification by increasing calcium absorption without providing the K2 needed to direct calcium to bone rather than arteries. K2 is fat-soluble and should be taken with a fat-containing meal for optimal absorption. For comprehensive cardiovascular protection, the combination of K2 (180mcg MK-7), vitamin D (2,000-4,000IU), and omega-3 fatty acids (1,000-2,000mg EPA/DHA) is one of the most evidence-complete cardiovascular support stacks available.
Leave a Reply